
    
      This is a Phase II randomized study to evaluate the effectiveness of Sirolimus in treating
      and preventing squamous cell skin cancer carcinoma using a Simon's 2-stage design. As part of
      the study, after the biopsy results of the skin cancer show squamous cell carcinoma and
      consent had been obtain, the participant will begin taking Sirolimus. The calcineurin
      inhibitor (tacrolimus or cyclosporine) will be discontinued once the transplant doctors find
      that the participants Sirolimus is therapeutic by checking blood tests once a week x 3 weeks.
      Approximately 5 weeks after starting Sirolimus, the squamous cell skin cancer will be removed
      by a surgeon. Participant next follow up visit for the study is scheduled one year
      post-operatively. .The study will look at your squamous cell skin cancer under the microscope
      to see if sirolimus had any effect at treating your squamous cell skin cancer.
    
  